Immune modulatory effects of oncogenic KRAS in cancer
Oncogenic signalling has been historically associated with sustained cancer cell-intrinsic proliferation, however its role in promoting tumour immunoresistance has also become evident. Here, Hamarsheh and colleagues review and discuss the preclinical work on the immune modulatory effects of oncogeni...
Guardado en:
Autores principales: | Shaima’a Hamarsheh, Olaf Groß, Tilman Brummer, Robert Zeiser |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bab2055f90cc4a4aa21071e579d430b6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation
por: Shaima’a Hamarsheh, et al.
Publicado: (2020) -
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
por: Naiara Santana-Codina, et al.
Publicado: (2018) -
Oncogenic KRAS: Signaling and Drug Resistance
por: Hyeon Jin Kim, et al.
Publicado: (2021) -
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
por: Gongmin Zhu, et al.
Publicado: (2021) -
KRAS insertion mutations are oncogenic and exhibit distinct functional properties
por: Yasmine White, et al.
Publicado: (2016)